Resistance to Proteasome Inhibitors in Cancer

Molecular Mechanisms and Strategies to Overcome Resistance

Nonfiction, Health & Well Being, Medical, Specialties, Oncology, Medical Science, Pharmacology
Cover of the book Resistance to Proteasome Inhibitors in Cancer by , Springer International Publishing
View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart
Author: ISBN: 9783319067520
Publisher: Springer International Publishing Publication: September 16, 2014
Imprint: Springer Language: English
Author:
ISBN: 9783319067520
Publisher: Springer International Publishing
Publication: September 16, 2014
Imprint: Springer
Language: English

The book explores cutting-edge strategies to overcome proteasome inhibitor resistance, including the second generation 20S proteasome inhibitors, novel combinational therapies, and new targets in the ubiquitin-proteasome pathway (e.g., ubiquitin E3 ligases, deubiquitinases, 19S proteasomal ATPases, histone deacetylases, oxidative stress and proteotoxic stress pathways and pharmacogenomic signature profiling) in resistant cancer cells. The mechanisms of action and resistance of proteasome inhibitors, such as bortezomib and carfilzomib in human cancers, including multiple myeloma, mantle cell lymphoma, acute leukemia, and solid tumors are explored in depth in this volume.

This timely volume unveils the most current discoveries of the mechanisms behind proteasome inhibitor resistance, which will help illuminate the future of cancer therapies.

View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart

The book explores cutting-edge strategies to overcome proteasome inhibitor resistance, including the second generation 20S proteasome inhibitors, novel combinational therapies, and new targets in the ubiquitin-proteasome pathway (e.g., ubiquitin E3 ligases, deubiquitinases, 19S proteasomal ATPases, histone deacetylases, oxidative stress and proteotoxic stress pathways and pharmacogenomic signature profiling) in resistant cancer cells. The mechanisms of action and resistance of proteasome inhibitors, such as bortezomib and carfilzomib in human cancers, including multiple myeloma, mantle cell lymphoma, acute leukemia, and solid tumors are explored in depth in this volume.

This timely volume unveils the most current discoveries of the mechanisms behind proteasome inhibitor resistance, which will help illuminate the future of cancer therapies.

More books from Springer International Publishing

Cover of the book Tools for High Performance Computing 2015 by
Cover of the book Knocking in Gasoline Engines by
Cover of the book Antitrust: The Person-centred Approach by
Cover of the book Precision Molecular Pathology of Lung Cancer by
Cover of the book Optimal Search for Moving Targets by
Cover of the book Urban Sustainability: Policy and Praxis by
Cover of the book Dams, Displacement and Development by
Cover of the book Agent-Mediated Electronic Commerce. Designing Trading Strategies and Mechanisms for Electronic Markets by
Cover of the book The Sociolinguistics of Academic Publishing by
Cover of the book Scalable and Near-Optimal Design Space Exploration for Embedded Systems by
Cover of the book Cooperative Coordination and Formation Control for Multi-agent Systems by
Cover of the book Difficult Decisions in Colorectal Surgery by
Cover of the book Advances in Affective and Pleasurable Design by
Cover of the book Soft Modeling in Industrial Manufacturing by
Cover of the book The Bright Side and the Dark Side of Patient Empowerment by
We use our own "cookies" and third party cookies to improve services and to see statistical information. By using this website, you agree to our Privacy Policy